Morocco’s Sothema to produce China’s Sinopharm vaccine | Inquirer News

Morocco’s Sothema to produce China’s Sinopharm vaccine

/ 11:21 AM July 06, 2021

sinopharm vaccine

Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS FILE PHOTO

RABAT — Moroccan pharmaceutical firm Sothema will soon start production of 5 million doses a month of China’s Sinopharm COVID-19 vaccine in the North African country, state news agency MAP reported on Monday.

The announcement was made at a ceremony chaired by King Mohammed VI during which the Moroccan government, Sinopharm and Sothema, whose formal name is Société Thérapeutique Marocaine, also signed deals to produce the vaccine in Morocco, which has a population of about 36 million.

Article continues after this advertisement

At the same event, the Moroccan government also signed a deal with Sweden’s Recipharm to set up a plant in Morocco to produce other key vaccines.

FEATURED STORIES

Morocco, which rolled out a COVID-19 vaccination campaign in January, has inoculated more people against the virus than other African countries. It had administered 19.23 million doses of the Sinopharm and AstraZeneca vaccines as of July 5.

The country has received 20.4 million doses so far and plans to inoculate everyone over the age of 17. Morocco has registered 534,550 COVID-19 infections and 9,319 deaths due to the virus.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: China, Health, Morocco, Sinopharm

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.